-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VTP-200
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTP-200 Drug Details VTP-200 is under development for the treatment of HPV associated cervical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VTP-600
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTP-600 Drug Details VTP-600 is under development for the treatment of non-squamous  non-small cell...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VTP-800
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry VTP-800 Drug Details VTP-800 is under development for the treatment of castration resistant prostate...
-
Product Insights
Prostate Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Prostate cancer usually occurs in older men. Its symptoms include problems while urinating, decreased force in the stream of urine, blood in the urine, pain in the lower back, hips, or thighs, bone pain, and erectile dysfunction. The Prostate Cancer pipeline market research report provides comprehensive information on the therapeutics under development for Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the...
-
Product Insights
Cervical Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Cervical Cancer Drugs Market Report Overview Most cervical cancer is caused by a virus called human papillomavirus, or HPV. Its symptoms of cervical cancer may include abnormal vaginal bleeding, such as bleeding after sex (vaginal intercourse), bleeding after menopause, bleeding, spotting between periods, and having longer or heavier (menstrual) periods than usual. Key Targets Programmed Cell Death Protein 1, Human Papillomavirus Protein E7, Programmed Cell Death 1 Ligand 1, Human Papillomavirus Protein E6, Cytotoxic T Lymphocyte Protein 4, Vascular Endothelial...
-
Product Insights
Hepatitis B Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Hepatitis B virus can cause an acute illness with symptoms that last several weeks, including yellowing of the skin and eyes (jaundice), dark urine, extreme fatigue, nausea, vomiting, and abdominal pain. The Hepatitis B pipeline market research report provides comprehensive information on the therapeutics under development for Hepatitis B, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Herpes Zoster (Shingles) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Shingles (herpes zoster) is caused by the varicella-zoster virus. Symptoms may include fever and chills, headache, joint pain, and swollen glands. The predisposing factors include age and a weakened immune system. The Herpes Zoster (Shingles) pipeline drugs market research report provides an overview of the Herpes Zoster (Shingles) (Infectious Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Herpes Zoster (Shingles) (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action...
-
Product Insights
Human Papillomavirus (HPV) Associated Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Risk factors of Human Papillomavirus (HPV) Associated Cancer includes smoking, weakened immune system, long-term oral contraceptive use, and chronic inflammation. The Human Papillomavirus (HPV) Associated Cancer pipeline drugs market research report provides an overview of the Human Papillomavirus (HPV) Associated Cancer (Oncology) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Human Papillomavirus (HPV) Associated Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule...
-
Sector Analysis
Coronavirus Disease 2019 (COVID-19) Vaccines – Contract Development and Manufacturing Landscape
This expert trend report is a comprehensive look at the contract manufacturing landscape surrounding COVID-19 Vaccine in 2020, including analysis of pipeline drugs, clinical trials, CMO activity, Contract Manufacturing Service Agreements, and funding for manufacturing of COVID-19 Vaccines. It is a critical source for strategic planning efforts and will improve understanding of crucial components of the supply chain that will provide insights for supplier selection and management.
-
Sector Analysis
Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies
Emerging infectious diseases (EIDs) are characterized by unpredictable incidence and clinical patterns that pose unique challenges for vaccine development. As outbreaks of Ebola virus, Zika virus, and other EIDs have occurred in the past decade, drug developers and global health organizations are turning to novel funding and clinical trial paradigms to improve epidemic preparedness. This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and...